Comparative Pharmacology
Head-to-head clinical analysis: HYDROPANE versus MICROZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROPANE versus MICROZIDE.
HYDROPANE vs MICROZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thiazide diuretic; inhibits sodium chloride cotransporter in distal convoluted tubule, increasing excretion of sodium and water, and reducing plasma volume.
Inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the nephron, reducing reabsorption of sodium and chloride, leading to increased excretion of water and electrolytes, and a decrease in blood volume and peripheral vascular resistance.
50–100 mg orally once daily, maximum 200 mg daily
12.5-25 mg orally once daily for hypertension; 25-100 mg orally once daily for edema.
None Documented
None Documented
Terminal elimination half-life is approximately 8-15 hours in patients with normal renal function; may be prolonged in renal impairment.
Terminal elimination half-life: 8-12 hours (prolonged in renal impairment; up to 30 hours in severe insufficiency).
Renal (approximately 50% as unchanged drug) and hepatic metabolism to inactive metabolites; fecal elimination accounts for about 10%.
Primarily renal (approximately 70% unchanged drug; remainder as metabolites and conjugates); minimal biliary/fecal (<10%).
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic